Pre-made Ficlatuzumab biosimilar ( Whole mAb, anti-HGF therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-212
Anti-HGF therapeutic antibody (Pre-made Ficlatuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-HGF therapeutic antibody (Pre-made Ficlatuzumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||AVEO Oncology;AVEO Pharmaceuticals;Dana-Farber Cancer Institute;University of Arizona Cancer Center;University of California at San Francisco|
|Conditions Active||Head and neck cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Pancreatic cancer|
|Conditions Discontinued||Lymphoma;Multiple myeloma;Solid tumours;Glioblastoma|